Evkeeza FDA Approval History
FDA Approved: Yes (First approved February 11, 2021)
Brand name: Evkeeza
Generic name: evinacumab-dgnb
Previous name: evinacumab
Dosage form: Injection
Company: Regeneron Pharmaceuticals, Inc.
Treatment for: High Cholesterol, Familial Homozygous
Evkeeza (evinacumab-dgnb) is an angiopoietin-like 3 (ANGPTL3) inhibitor indicated as an adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 12 years and older, with homozygous familial hypercholesterolemia (HoFH).
Development Timeline for Evkeeza
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.